What is BioSurfaces?
BioSurfaces LLC is at the forefront of developing advanced medical devices and specialized coatings. Utilizing FDA-approved polymers and proprietary electrospinning technology, the company produces cutting-edge in vitro research tools, microphysiological systems, and cell therapy delivery solutions. These innovations are designed to significantly enhance patient healing processes and improve the treatment of various diseases. BioSurfaces actively engages in strategic collaborations with leading entities such as Takeda, the National Institutes of Health (NIH), and Corning, further validating and advancing its Bio-Spun nanofiber technology. The company's primary market focus is on healthcare providers and researchers seeking sophisticated advancements in drug delivery and tissue engineering.
How much funding has BioSurfaces raised?
BioSurfaces has raised a total of $308K across 2 funding rounds:
Debt
$150K
Debt
$158K
Debt (2020): $150K with participation from PPP
Debt (2021): $158K led by PPP
Key Investors in BioSurfaces
PPP
Public-Private Partnership
PPP
Public-Private Partnership
Undisclosed Investor
An undisclosed investor participated in the company's funding round, contributing to the overall capital raised.
What's next for BioSurfaces?
The substantial late-stage funding positions BioSurfaces for significant scaling and market penetration. With a focus on its proprietary Bio-Spun nanofiber technology and ongoing collaborations, the company is poised to expand its product offerings in advanced medical devices and coatings. Future growth is expected to be driven by the increasing demand for innovative solutions in drug delivery, tissue engineering, and personalized medicine, solidifying BioSurfaces' role as a key player in the healthcare technology landscape.
See full BioSurfaces company page
